Skip to main content
Explore URMC
menu
URMC / Labs / Maquat Lab / News

 

News

20222021202020192018

Lynne Maquat Receives Advisory Appointment at International Centre for Genetic Engineering and Biotechnology

Friday, August 12, 2022

Lynne MaquatLynne E. Maquat, Ph.D., the J. Lowell Orbison Endowed Chair and Professor of Biochemistry and Biophysics, Oncology and Pediatrics at the University of Rochester School of Medicine & Dentistry has been elected a member of the Council of Scientific Advisers (CSA) of the International Centre for Genetic Engineering and Biotechnology (ICGEB). Also the founding director of the University of Rochester’s Center for RNA Biology, Maquat will serve as a member of the Council for a term of three years, beginning in July 2022.

The ICGEB is an intergovernmental organization that runs over 45 state-of-the-art laboratories in Trieste, Italy, New Delhi, India and Cape Town, South Africa. If forms an interactive network with close to 70 member states, and plays a key role in biotechnology by promoting research excellence, training, and technology transfer to industry. The Council of Scientific Advisers is composed of fifteen “eminent” scientists who are active in the life sciences at the international level. Maquat will work together with fellow advisors to provide ICGEB member states with effective training programs and dedicated research projects.

With this appointment, Maquat has held a dozen international advisory positions since 2000. In addition to the ICGEB, she is currently a member of the Scientific Advisory Board for the Max Planck Institute for Molecular Genetics in Berlin, Germany and a member of the Medical Advisory Board for the Canada Gairdner International Awards and The Gairdner Foundation in Canada.

Maquat is the second member of the University of Rochester community to be elected a member of the Council of Scientific Advisers. Arthur Kornberg, M.D., who earned his medical degree from the School of Medicine & Dentistry in 1941 and went on to receive the Nobel Prize in Physiology or Medicine in 1959, served as a scientific advisor to the ICGEB from 1995 to 2005.

Double Duty: Early Research Reveals how a Single Drug Delivers Twice the Impact in Fragile X

Monday, June 27, 2022

Like many neurological diseases, there’s a lot we don’t understand about fragile X syndrome. But, after studying the disorder for several years, Lynne Maquat’s lab knew two important things: the enzyme AKT, which plays a key role in cell growth and survival, and the quality control pathway known as NMD (nonsense-mediated mRNA decay), are both in overdrive in fragile X.

In a new study in the journal Molecular Cell, the team reveals how these two major players interact, highlighting a complex molecular dance that could inform the development of future treatments for fragile X syndrome.

Two paths to pursue 

AKT is a hub for cell signaling, helping cells communicate about important processes like cell growth, proliferation and protein production. When cells are stressed – for example, in cancer, diabetes, heart disease and neurological disorders, including fragile X – AKT can send too many (or too few) signals or messages as part of a cell survival mechanism.    

NMD is like a molecular guide that helps our cells make smart decisions that (in most cases) improve cellular function and contribute to good health. For example, NMD supports gene expression by flagging and destroying mRNAs (messenger RNAs) that are carrying faulty genetic instructions that could lead to disease. It also helps our cells adjust to changes in development and in their environment, and more rapidly respond to certain stimuli.

Read More: Double Duty: Early Research Reveals how a Single Drug Delivers Twice the Impact in Fragile X